Anemia of Chronic Kidney Disease

Singh, Ajay K.

doi:10.2215/cjn.05131107

Cited by 15 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanisms that control transcriptional activity have received prominent attention in recent years (summarized in Figure 2) (44). The true value of understanding mechanisms that underlie control of Epo expression may be the possible therapeutic solutions to overcome the transcriptional silencing of Epo, a hallmark of CKD (47). While hypoxia is the principal stimulus for Epo expression under physiologic conditions, Epo transcription is silenced in chronically diseased kidneys, despite the hypoxic conditions that are a hallmark of renal fibrogenesis (34).…”

Section: Regulation Of Epo Productionmentioning

confidence: 99%

Physiology of the Renal Interstitium

Zeisberg

Kalluri

2015

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Long overlooked as the virtual compartment and then strictly characterized through descriptive morphologic analysis, the renal interstitium has finally been associated with function. With identification of interstitial reninand erythropoietin-producing cells, the most prominent endocrine functions of the kidney have now been attributed to the renal interstitium. This article reviews the functional role of renal interstitium.

show abstract

Section: Regulation Of Epo Productionmentioning

confidence: 99%

Physiology of the Renal Interstitium

Zeisberg

Kalluri

2015

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Peningkatan kadar spermidin dan spermin serum pada penderita ESRD tidak hanya memberi efek penghambatan pada eritropoesis saja, tetapi juga dapat menghambat trombopoesis dan granulopoesis. Karena ketidakspesifikan, trombositopenia, dan leukopenia bukan merupakan karakteristik dari uremia, maka dapat disimpulkan bahwa spermidin dan spermin tidak memiliki fungsi yang signifikan pada patogenesis anemia pada ESRD (Singh, 2008).…”

Section: Tabel 3 Lamanya Menjalani Hemodialisisunclassified

Menurunnya Kadar Hemoglobin Pada Penderita End Stage Renal Disease (Esrd) Yang Menjalani Hemodialisis Di Kota Malang

Agustina¹,

Purnomo²

2019

Prosiding Seminar Nasional 2018 “ Peran Dan Tanggung Jawab Tenaga Kesehatan Dalam Mendukung Program Kesehatan Nasional”

View full text Add to dashboard Cite

Incidence of kidney failure in Indonesia has increased by 20% annually, an estimated 70,000 people in 2011, 4,000-5,000 people are detected with end-stages renal failure and undergoing hemodialysis. The hemodialysis process causes some blood trapped or left in the hemodialysis device, some red blood cells are damaged and folic acid decreases. The aims of this study was to know the difference of hemoglobin (Hb) profile in End Stages Renal Disease (ESRD) patients based on duration of hemodialysis at RS "S" Malang. The research method used a comparative design with a sample of 100 respondents. Anova test showed the difference of Hb level profile in ESRD patients based on duration of hemodialysis from 1 year up to 10 years (p = 0,03; α = 0,05), which means that the longer the hemodialysis then the Hb level decreases. Anemia is a complication of ESRD, the decrease in Hb resulting from disruption of the production of the hormone erythropoetin, in addition hemodialysis process also exacerbates the degree of anemia where some red blood cells trapped in hemodialysis, red blood cells are damaged, and folic acid decreased due to dissolved in fluid dialysis. Furthermore, it is necessary to examine related factors that cause the decrease in Hb in patientss with ESRD with hemodialysis therapy both intrinsic and extrinsic factors. PENDAHULUANEnd Stage Renal Disease (ESRD) merupakan suatu proses kerusakan sel-sel ginjal dengan rentang waktu lebih dari 3 bulan. ESRD dapat menimbulkan gejala berupa laju filtrasi glomerular di bawah 60 mL/men/1.73 m2, atau di atas nilai tersebut namun disertai dengan kelainan sedimen urin. Proses perjalanan penyakit dari ESRD disebabkan oleh berbagai etiologi yang secara progresif menurunkan fungsi dari ginjal, sehingga lama-kelamaan ginjal akan mengalami kehilangan fungsinya yang disebut dengan gagal ginjal. Kerusakan sel ginjal bersifat PROSIDING SEMINAR NASIONAL 2018 Peran dan Tanggung Jawab Tenaga Kesehatan dalam Mendukung Program Kesehatan

show abstract

“…Anemia management in CKD patients mostly relies on the use of EPO (Gombotz, 2012). It is a widely accepted treatment, as well as the first-line therapy for anemia in CKD patients (Singh, 2008). Although it has many advantages, EPO drug is expensive and, therefore, burdensome for patients who must take it (Mikhail et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Evaluasi terapi erytropoetin pada pasien hemodialisa di rumah sakit PKU Muhammadiyah Yogyakarta

Adnan¹,

Dania²,

Supadmi³

2018

Pharmaciana

View full text Add to dashboard Cite

Most of the patients with end-stage renal disease who undergo hemodialysis receive erythropoietin (EPO) therapy for anemia treatment. Anemia with EPO deficiency is a common complication of chronic kidney disease (CKD). EPO therapy is expected to improve anemia and quality of life of patients. This analytic observational study was conducted in a cross-sectional design. It aimed to identify the difference in red blood cell profiles, namely hemoglobin (Hb), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular Hemoglobin Concentration (MCHC), and quality of life of CKD patients on EPO and non-EPO therapy at PKU Muhammadiyah Hospital in Yogyakarta. The inclusion criteria were PGK ICD N18.9 outpatients who received hemodialysis therapy at this hospital and were literate, able to understand the questionnaire, and willing to be a respondent. The results showed that there was no significant difference (p>0,05) between the red blood cells (Hb, MCV, MCH, MCHC) of the EPO and non-EPO therapy groups. The correlation between the EPO and the quality of life of patients in all of the KDQOL domains was p> 0.05. Aside from the insignificant difference between the EPO and non-EPO therapy groups, the research concluded that there was no correlation between either the EPO or the non-EPO therapy with the quality of life of hemodialysis patients.

show abstract

Anemia of Chronic Kidney Disease

Cited by 15 publications

References 32 publications

Physiology of the Renal Interstitium

Physiology of the Renal Interstitium

Menurunnya Kadar Hemoglobin Pada Penderita End Stage Renal Disease (Esrd) Yang Menjalani Hemodialisis Di Kota Malang

Evaluasi terapi erytropoetin pada pasien hemodialisa di rumah sakit PKU Muhammadiyah Yogyakarta

Contact Info

Product

Resources

About